You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm has already received CE marking for its nanofluidic point-of-care assay, which could provide rapid identification of sepsis in patients.
Data presented at ASCO showing 76 percent of cancer patients responded to larotrectinib could lead to the availability of the first tissue-agnostic targeted drug.
Collaborators have created an atlas that compares available PD-L1 IHC assays and reveals areas of debate, including challenges encountered by clinicians.
A year-long clinical trial at three hospitals found that price transparency alone may not lead to significant changes in a clinician's test requests.
A simple stool-based immunochemical test has shown promise during early trials in accurately ruling out the need for unnecessary colonoscopies.
Grail plans to enroll up to 120,000 women who have been screened via mammogram, to train and validate its NGS-based early detection cancer test.
Gencurix aims to achieve US FDA 510(k) clearance for its GenesWell BCT breast cancer prognostic test next year.
Genelex is hoping that a recently published randomized-controlled trial will help it get on better footing with Medicare.
Geneticure has raised around $1.1 million to fund the study, which may very well be the largest prospective RCT for personalization of high blood pressure treatment.
Under the deal, Novartis will access patients who have used Perthera's Precision Cancer Analysis service, which facilitates molecular profiling of cancers.